These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34817414)

  • 1. Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.
    Singh RP; Adkison KK; Baker M; Parasrampuria R; Wolstenholme A; Davies M; Sewell N; Brothers C; Buchanan AM
    Pediatr Infect Dis J; 2022 Mar; 41(3):230-237. PubMed ID: 34817414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
    Singh RP; Shaik JSB; Skoura N; Joshi S; Shreeves T; Casillas L; Buchanan AM
    J Acquir Immune Defic Syndr; 2018 Dec; 79(5):631-638. PubMed ID: 30239425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants.
    Singh RP; Adkison K; Wolstenholme A; Hopking J; Wynne B
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):985-993. PubMed ID: 34265164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food.
    Weller S; Chen S; Borland J; Savina P; Wynne B; Piscitelli SC
    J Acquir Immune Defic Syndr; 2014 Aug; 66(4):393-8. PubMed ID: 24798770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study.
    Brooks KM; Kiser JJ; Ziemba L; Ward S; Rani Y; Cressey TR; Masheto GR; Cassim H; Deville JG; Ponatshego PL; Patel F; Aurpibul L; Barnabas SL; Mustich I; Coletti A; Heckman B; Krotje C; Lojacono M; Yin DE; Townley E; Moye J; Majji S; Acosta EP; Ryan K; Chandasana H; Brothers CH; Buchanan AM; Rabie H; Flynn PM;
    Lancet HIV; 2023 Aug; 10(8):e506-e517. PubMed ID: 37541705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.
    Dumitrescu TP; Peddiraju K; Fu C; Bakshi K; Yu S; Zhang Z; Tenorio AR; Spancake C; Joshi S; Wolstenholme A; Adkison K
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):189-202. PubMed ID: 31724343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure.
    Roskam-Kwint M; Bollen P; Colbers A; Duisenberg-van Essenberg M; Harbers V; Burger D
    J Antimicrob Chemother; 2018 Sep; 73(9):2430-2434. PubMed ID: 29796595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.
    Chandasana H; Singh R; Adkison K; Ait-Khaled M; Pene Dumitrescu T
    Antimicrob Agents Chemother; 2024 May; 68(5):e0150423. PubMed ID: 38587380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
    Greig SL; Deeks ED
    Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
    Blackman AL; Heil EL; Devanathan AS; Pandit NS
    Antivir Ther; 2020; 25(2):115-119. PubMed ID: 32341207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
    Ruel TD; Acosta EP; Liu JP; Gray KP; George K; Montañez N; Popson S; Buchanan AM; Bartlett M; Dayton D; Anthony P; Brothers C; Vavro C; Singh R; Koech L; Vhembo T; Mmbaga BT; Pinto JA; Dobbels EFM; Archary M; Chokephaibulkit K; Ounchanum P; Deville JG; Hazra R; Townley E; Wiznia A;
    Lancet HIV; 2022 May; 9(5):e332-e340. PubMed ID: 35489377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers.
    Bevers LAH; Kamphuis AEM; van der Wekken-Pas LCW; Leisegang R; Burger DM; Colbers A
    Clin Pharmacokinet; 2024 May; 63(5):721-728. PubMed ID: 38573477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
    Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
    Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
    Orkin C; DeJesus E; Sax PE; Arribas JR; Gupta SK; Martorell C; Stephens JL; Stellbrink HJ; Wohl D; Maggiolo F; Thompson MA; Podzamczer D; Hagins D; Flamm JA; Brinson C; Clarke A; Huang H; Acosta R; Brainard DM; Collins SE; Martin H; ;
    Lancet HIV; 2020 Jun; 7(6):e389-e400. PubMed ID: 32504574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
    Khatri A; Trinh R; Zhao W; Podsadecki T; Menon R
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6244-51. PubMed ID: 27503645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy.
    Chaudhary S; Nair AB; Shah J; Gorain B; Jacob S; Shah H; Patel V
    AAPS PharmSciTech; 2021 Apr; 22(3):127. PubMed ID: 33835317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
    Rojas J; de Lazzari E; Negredo E; Domingo P; Tiraboschi J; Ribera E; Abdulghani N; Puig J; Mateo MG; Podzamczer D; Gutierrez MM; Paredes R; Clotet B; Gatell JM; Blanco JL; Martínez E;
    Lancet HIV; 2021 Aug; 8(8):e463-e473. PubMed ID: 34358497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy.
    Lombardi F; Belmonti S; Borghetti A; Ciccullo A; Fabbiani M; Di Giambenedetto S
    Infez Med; 2020 Sep; 28(3):461-463. PubMed ID: 32920587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.